Oral administration of human carbonic anhydrase I suppresses colitis in a murine inflammatory bowel disease model

The incidence of inflammatory bowel disease (IBD) is increasing; hence, effective treatments are warranted. The therapeutic effect of human carbonic anhydrase I (hCA I) in IBD remains unknown. Therefore, we investigated whether oral tolerization to hCA I would induce antigen-specific protection from...

Descripción completa

Detalles Bibliográficos
Autores principales: Tange, Kazuhiro, Yagi, Sen, Takeshita, Eiji, Abe, Masanori, Yamamoto, Yasunori, Tomida, Hideomi, Kawamura, Tomoe, Hanayama, Masakazu, Matsuura, Bunzo, Ikeda, Yoshiou, Hiasa, Yoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606376/
https://www.ncbi.nlm.nih.gov/pubmed/36289244
http://dx.doi.org/10.1038/s41598-022-22455-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606376/
https://www.ncbi.nlm.nih.gov/pubmed/36289244
http://dx.doi.org/10.1038/s41598-022-22455-y

Ejemplares similares